ADAM17 and cancer: Specific a-disintegrin and metalloproteinase (ADAM) are overexpressed in many human cancers and related with poor clinical outcomes and tumor progression, silencing FoxM1 led to an inhibition of cell proliferation, tumor growth induced by ADAM-17 in hilar cholangiocarcinoma [39].